Wildfires Blanket Southern California With Smoky Air, Threatening Health of Millions

Published Date: 10 Jan 2025

The risks and how to protect yourself

Read Full News

Latest News

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Where Does Ameluz PDT Fit Alongside Mohs Surgery? Neal Bhatia, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

News All Time

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

Competition, Burnout, and the Cost of Always Saying 'Yes' as a Clinician Adam Friedman, MD, FAAD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today Lisa A. Swanson, MD

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

Skin Angels and the Atopic Dermatitis Pipeline, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD Manju Dawkins, MD

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD Steven Daveluy, MD, FAAD

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know Tim Smith

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Recommended News For You

'Sleep ALL night' program helps children with leukemia sleep better during treatment

Q&A: Odds of surviving cancer drop drastically when credit score dips

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

Is Exercise an Effective Treatment for Prostate Cancer?

A novel blood test may enable the early identification of common, fatal cancers.

Two-part prodrug system activates immune attack only in tumor's unique environment

Recommended Articles For You

The Latest Advances in Glioblastoma Treatment and Prevention  

Functional Genomics of Treatment-Resistant Anemia 

ADCs and Bispecific Antibodies: Advancing the Future of Cancer Immunotherapy 

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

2.

Clinical trial is testing whether heavy lifting could combat cancer side effects

3.

NIH research cuts leave cancer patient facing hard choice

4.

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

5.

A video animation guide to assist young people who are fatigued from cancer.

1.

Hematology Drug Preparation Safety: Ensuring Efficacy and Reducing Risks in Clinical Practice

2.

The Latest Advances in Glioblastoma Treatment and Prevention 

3.

AI-Assisted Real-Time Tumor Mapping During Surgery: Transforming Intraoperative Oncology

4.

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology

5.

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Understanding Anemia: Causes and Treatment

2.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

Signs and Symptoms of Leukemia

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot